Covid-19 Vaccine Effectiveness Assessment in Chile

Rafael Araos, MD

Alejandro Jara, Ph.D

vCovid – Ministry of Health, Chile

Disclosures

• No COI to disclose

Situation Report

Case-ICU conversion rate

Rollout of second doses

Rollout of boosters

Beginning of vaccine program

Vaccine Effectiveness

Assessments

National health fund (~80% Chile

population)

Final cohortvCovid

<16 yo, inactive insurance, hx of Covid-

19 (U07.1 & 2)

Vital statsEpi surveillance

Hosp. surveillanceComorbidities

National vaccine registry Immunized group(>14 d post

second dose)

Not vaccinated

Boosted group(>14 d post

booster)

Table 2: The Cohort

Table 3: The Cohort

Table 5: SARS-CoV-2 Infection

Table 6: Covid-19

Table 7: Hospital Admissions

Table 8: ICU Admissions

Table 9: Covid-19 Death?To early, zero deaths among boosted population

Conclusions

• We provide observational evidence to support that heterologous and

homologous booster shots were able to significantly increase the

effectiveness of primary immunization among people vaccinated with

inactivated vaccines.

Acknowledgments

• vCovid team

• Ministry of Health, Chile

• Universidad del Desarrollo

• Pontificia Universidad Católica de Chile